Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Vichi

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Viruses|November 11, 2022
Trajectories of CD4<sup>+</sup>/CD8<sup>+</sup> T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort StudyLucia Taramasso, Antonio Falletta, Elena Ricci, et al.
BMC Infectious Diseases|June 27, 2019
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional studyPaolo Maggi, Carmen R Santoro, Marco Nofri, et al.
Microbes and Infection|September 23, 2016
A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infectionMara Biasin, Manuela Sironi, Irma Saulle, et al.
International Journal of Antimicrobial Agents|December 6, 2014
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillanceGiordano Madeddu, Giuseppe V L De Socio, Elena Ricci, et al.
Open Forum Infectious Diseases|October 30, 2019
Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort StudyFrancesco Vadini, Federica Sozio, Giordano Madeddu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 26, 2013
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)Barbara Menzaghi, Elena Ricci, Laura Carenzi, et al.
Viruses|May 28, 2022
Reversibility of Central Nervous System Adverse Events in Course of ArtLucia Taramasso, Giancarlo Orofino, Elena Ricci, et al.
Plos One|June 21, 2017
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) projectNicola Squillace, Elena Ricci, Tiziana Quirino, et al.
Infection and Drug Resistance|May 8, 2018
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA ProjectPaola Bagella, Giuseppe Vl De Socio, Elena Ricci, et al.
BMC Infectious Diseases|April 14, 2023
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimensPaolo Maggi, Elena Delfina Ricci, Stefania Cicalini, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Viruses|November 11, 2022
Trajectories of CD4<sup>+</sup>/CD8<sup>+</sup> T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort StudyLucia Taramasso, Antonio Falletta, Elena Ricci, et al.
BMC Infectious Diseases|June 27, 2019
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional studyPaolo Maggi, Carmen R Santoro, Marco Nofri, et al.
Microbes and Infection|September 23, 2016
A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infectionMara Biasin, Manuela Sironi, Irma Saulle, et al.
International Journal of Antimicrobial Agents|December 6, 2014
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillanceGiordano Madeddu, Giuseppe V L De Socio, Elena Ricci, et al.
Open Forum Infectious Diseases|October 30, 2019
Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort StudyFrancesco Vadini, Federica Sozio, Giordano Madeddu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 26, 2013
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)Barbara Menzaghi, Elena Ricci, Laura Carenzi, et al.
Viruses|May 28, 2022
Reversibility of Central Nervous System Adverse Events in Course of ArtLucia Taramasso, Giancarlo Orofino, Elena Ricci, et al.
Plos One|June 21, 2017
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) projectNicola Squillace, Elena Ricci, Tiziana Quirino, et al.
Infection and Drug Resistance|May 8, 2018
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA ProjectPaola Bagella, Giuseppe Vl De Socio, Elena Ricci, et al.
BMC Infectious Diseases|April 14, 2023
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimensPaolo Maggi, Elena Delfina Ricci, Stefania Cicalini, et al.
Pageof 6